Drug Profile
Hantavirus vaccine - Pierre Fabre/Institut Rega
Latest Information Update: 21 Aug 2007
Price :
$50
*
At a glance
- Originator Pierre Fabre; Rega Institute for Medical Research
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hantavirus infections
Most Recent Events
- 19 Oct 2005 No development reported - Preclinical for Hantavirus infections in Belgium (unspecified route)
- 19 Oct 2005 No development reported - Preclinical for Hantavirus infections in France (unspecified route)
- 28 Nov 2002 This vaccine is still in active development